Loading stock data…
CRSP
$54.01-0.82 (-1.50%)
After Hours$54.01+0.00 (+0.00%)· Last close May 11
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CRISPR Therapeutics AG in the Healthcare sector is trading at $54.01. The stock is currently 31% below its 52-week high of $78.48, remaining 3.8% below its 200-day moving average. Technical signals show neutral RSI of 47 and bullish MACD crossover, explaining why CRSP maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$54.01
Potential Upside
5%
Whystock Fair Value$56.71
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus22 analysts
Buy
Mean target$82.55+52.8%
Range$33.00 – $291.00
Fundamentals
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The compan...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.21B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.74
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-31.33%
Volume
Today's trading volume
1.32M
Recent News
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?
The biotech's innovative platform could pay off.
VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings
Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is It Time To Reconsider CRISPR Therapeutics (CRSP) After A 58% One Year Rally?
Before you decide whether CRISPR Therapeutics stock looks attractive at around US$52.38, it helps to ask a simple question: what are you actually paying for compared with what the business might be worth? Over the last week the stock return is 0.6%, over the last month it is 5.8%, and over the last year it is 58.0%, while the year-to-date return is a 2.6% decline and the three- and five-year returns are 17.4% and 49.4% declines respectively, which may catch the eye of both momentum fans and...
VRTX's Q1 Earnings Beat Estimates, New Products Aid Sales Growth
Vertex tops Q1 estimates as revenues climb 8% on strong CF drug demand and new product gains. Its pipeline has advanced and its 2026 guidance reaffirmed.